Bio Rad Laboratories Inc.

Bio-Rad Laboratories Inc., a subsidiary of Bio-Rad Laboratories, Inc. and a large for-profit manufacturer of life science research and clinical diagnostic products headquartered in Hercules, California, supplies laboratory instrumentation, reagents, consumables, and diagnostic systems to federal agencies as a prime contractor (100% of awards). The company competes full-and-open across all federal agencies without set-aside participation.

Bio-Rad's federal footprint centers on life sciences diagnostics and laboratory equipment manufacturing. The vendor manufactures advanced diagnostic instrumentation, quality control materials, PCR systems (including CFX Opus and QX200 droplet digital platforms), immunoassay analyzers (Bio-Plex multiplex systems), serological automated analyzers (GEENIUS HIV testing platform and EVOLIS Vitamin D analyzer), and specialized reagents and consumables supporting federal healthcare, research, and military medical readiness operations. Representative work includes a single-award indefinite delivery contract with the Defense Health Agency (awarded July 11, 2025, ceiling $6.9 million, through September 29, 2030) for serological automated analyzers supporting HIV and Hepatitis C testing in military entrance processing, with a $1.75 million delivery order issued September 30, 2025; a $3.4 million purchase order from the Defense Health Agency (awarded October 1, 2025, through September 30, 2030) for pathology testing requirements; a $1.4 million delivery order from the Defense Health Agency (awarded October 1, 2024) for Lyphochek quality control reagents through September 30, 2029; and recurring quarterly purchase orders from the Federal Medical Center Rochester for Bio-Rad Variant II analyzer rental and biological products, typically $3.7 thousand per quarter.

Customer concentration sits with military and Veterans Affairs medical operations. The Defense Health Agency leads by dollar value (42 awards, $49.1 million combined potential value), followed by the Department of the Army Medical Command (174 awards, $39.7 million), the Department of the Navy Bureau of Medicine and Surgery (129 awards, $8 million), and Veterans Integrated Service Network 2 (89 awards, $8 million). These five customers represent 56% of combined potential value across the portfolio. By award count, the Indian Health Service ranks first (209 awards, $4.1 million), reflecting high-volume, lower-dollar procurement of laboratory supplies and quality control materials across tribal health facilities.

Bio-Rad places work under multiple government vehicles. The "Invitro Diagnostics, Reagents, Test" vehicle carries the largest task-order count (230 task orders, $6.6 million combined value), followed by the Indefinite Delivery Contract HHSI242201000001I with the Department of Health and Human Services (43 task orders, $260 thousand). The vendor holds a single-award BPA with the Department of the Air Force (awarded October 22, 2021, ceiling $447,891, through October 22, 2026) for GEENIUS HIV test kits and reagents, and a single-award IDC with Veterans Integrated Service Network 2 (awarded January 1, 2023, ceiling $39,120.35, through December 31, 2027) for GEENIUS HIV testing systems.

Activity has declined year over year — 34 awards in 2022 and 2023, 21 in 2024, 27 in 2025, and 9 through mid-2026 to date — suggesting a recompete cliff of minimal scale (8 awards worth $484 thousand reaching completion in the next twenty-four months). Bio-Rad operates 4,204 prime awards in the source data spanning federal healthcare, research, and diagnostic agencies, with 37% of combined potential value obligated ($73 million of $199.7 million). The vendor's work is grounded in laboratory equipment and in-vitro diagnostic substance manufacturing (651 awards under NAICS 32844), analytical laboratory instrument manufacturing (409 awards), and medical/surgical instrument supply (474 awards under PSC code 6650 Medical and Surgical Instruments, Equipment, and Supplies). One disclosed sub-award places Bio-Rad under Mriglobal (November 15, 2024) for a Mycobacterium tuberculosis quality assessment program supplying AutoDG and QX200 droplet digital PCR systems.